177 related articles for article (PubMed ID: 17700271)
1. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Kartal ED; Alpat SN; Ozgunes I; Usluer G
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
[TBL] [Abstract][Full Text] [Related]
2. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy.
Shafa S; Borum ML; Igiehon E
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):122-3. PubMed ID: 19959941
[No Abstract] [Full Text] [Related]
3. Reversible alopecia universalis during treatment with PEG-interferon and ribavirin for chronic hepatitis C.
Taliani G; Biliotti E; Capanni M; Tozzi A; Bresci S; Pimpinelli N
J Chemother; 2005 Apr; 17(2):212-4. PubMed ID: 15920908
[TBL] [Abstract][Full Text] [Related]
4. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
5. Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege.
Ito T; Suzuki T; Funakoshi A; Tokura Y
Eur J Dermatol; 2014; 24(5):631-3. PubMed ID: 25115439
[No Abstract] [Full Text] [Related]
6. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
7. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Verma P; Dayal S; Jain VK; Amrani A
J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
[TBL] [Abstract][Full Text] [Related]
8. Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report.
Gamal N; Brodosi L; Misciali C; Patrizi A; Vukatana G; Malavolta N; Bernardi M; Andreone P
Ann Hepatol; 2014; 13(2):293-6. PubMed ID: 24558223
[TBL] [Abstract][Full Text] [Related]
9. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Grossmann Sde M; Teixeira R; de Aguiar MC; do Carmo MA
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):702-6. PubMed ID: 18679075
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C treatment and alopecia totalis.
Goh C
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S59-60. PubMed ID: 24326562
[TBL] [Abstract][Full Text] [Related]
12. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
Tavakoli-Tabasi S; Bagree A
J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
[TBL] [Abstract][Full Text] [Related]
14. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Moore MM; Elpern DJ; Carter DJ
Arch Dermatol; 2004 Feb; 140(2):215-7. PubMed ID: 14967798
[TBL] [Abstract][Full Text] [Related]
15. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
16. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
[TBL] [Abstract][Full Text] [Related]
17. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
Lee MY; Cho H; Kim YM; Lee JS
Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin.
Patrk I; Morović M; Markulin A; Patrk J
Dermatology; 2014; 228(1):42-6. PubMed ID: 24434490
[TBL] [Abstract][Full Text] [Related]
19. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
